Rawf8/iStock via Getty Images
Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic disease movement “Make America Healthy Again,” championed by Robert F. Kennedy Jr., President-elect Donald Trump’s nominee for HHS Secretary.
In a research